61 citations
,
September 2008 in “Biological & Pharmaceutical Bulletin” Finasteride almost fully depletes allopregnanolone in rat brains and enhances 20α-DHP, but doesn't change 3α-DHP levels.
32 citations
,
July 2016 in “PubMed” 17 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism”
June 2019 in “Journal of Drug Delivery and Therapeutics” 21 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 9 citations
,
August 1992 in “The Journal of Clinical Endocrinology and Metabolism”
September 2018 in “The Journal of Urology” 1 citations
,
September 2019 in “Journal of the Egyptian Women's Dermatologic Society (Print)” 61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 1 citations
,
June 2021 in “Singapore Medical Journal”
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
31 citations
,
April 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
20 citations
,
October 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
6 citations
,
July 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
May 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
218 citations
,
January 2012 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
137 citations
,
March 2006 in “Cns Drug Reviews” Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
64 citations
,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
38 citations
,
December 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.
32 citations
,
November 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride doesn't affect erections much, but may decrease libido in men.
13 citations
,
June 2018 in “Current Urology Reports” Hair loss drugs may cause sexual issues and infertility in men.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
July 2018 in “The Journal of Sexual Medicine” Finasteride does not negatively affect male reproductive function.